论文部分内容阅读
为了评价碳铂(Carboplatin,CBDCA)对未治疗的扩散期小细胞肺癌(ESSCLC)超强化化疗的疗效和毒性,治疗了25例 ESSCLC 患者,其中 Karnofsky 指数(%)低于80%者14例(56%),仅有对侧肺转移或胸膜渗出者7例(28%);胸外转移18例(7.2%),其中肝转移7例,骨转移3例,肝、骨均有转移者5例;其它部位转移者3例。治疗方法,CBDCA 500mg/m~2溶于5%葡萄糖1000ml,24小时静滴结束,每隔21天1次。CBDCA 静滴期
To evaluate the efficacy and toxicity of Carboplatin (CBDCA) on untreated diffuse small cell lung cancer (ESSCLC) for chemotherapy, 25 patients with ESSCLC were treated, of whom the Karnofsky index (%) was less than 80% (14 cases). 56%), only contralateral lung metastasis or pleural effusion in 7 cases (28%); chest metastases in 18 cases (7.2%), including liver metastases in 7 cases, bone metastases in 3 cases, liver and bone metastasis 5 cases; 3 cases of other site metastases. Treatment method, CBDCA 500mg/m~2 dissolved in 5% glucose 1000ml, 24 hours after the end of infusion, once every 21 days. CBDCA infusion